Because of the limited antidepressant efficacy during pharmacotherapy of major depressive disorder or anxiety disorders it is possible to use combinations of antidepressant agents with other drugs or physicians can prescribe some new antidepressive drug in order to improve results of pharmacotherapy. Inflammation can also play key role in the pathophysiology of major depressive disorder.
As a result of inflammation serotonin availability in the central nervous system is lower and neurotoxic molecules are produced instead of serotonin because of increased gene expression of cyclooxygenase-2, pro-inflammatory cytokines and other molecules. Based on these findings clinical and experimental trials evaluating efficacy of various nonsteroidal anti-inflammatory drugs as an adjunctive therapy to antidepressants were recently conducted.
Better treatment outcomes were observed most frequently after augmentation of antidepressant drugs with celecoxib.